Home>>Signaling Pathways>> Obesity, Appetite Control & Diabetes>> Diabetes>>AMP-Deoxynojirimycin

AMP-Deoxynojirimycin (Synonyms: AdamantanepentyldNM, AMP-DNJ, AMPdNM, N(5adamantane1ylmethoxypentyl)Deoxynojirimycin)

Catalog No.GC41406

The lipid messenger ceramide is converted to glucosylceramide by glucosylceramide synthase (GCS).

Products are for research use only. Not for human use. We do not sell to patients.

AMP-Deoxynojirimycin Chemical Structure

Cas No.: 216758-20-2

Size Price Stock Qty
500μg
$58.00
In stock
1mg
$111.00
In stock
5mg
$466.00
In stock
10mg
$816.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

The lipid messenger ceramide is converted to glucosylceramide by glucosylceramide synthase (GCS). In the reverse direction, non-lysosomal glucosylceramidase (GCase), also known as β-glucosidase 2 (BGD), cleaves the glucosyl moiety from glucosylceramide, liberating ceramide, which can be converted into sphingomyelin. AMP-deoxynojirimycin (AMP-dNM) is a hydrophobic derivative of dNM. It potently inhibits BGD (IC50 = 0.3 nM), less potently antagonizes GCS (IC50 = 25 nM), but only poorly inhibits other GCase isoforms. AMP-dNM has been shown to strongly suppress inflammation in a murine model of hapten-induced colitis, enhance insulin sensitivity in murine and rat models of insulin resistance, and induce sterol regulatory element-binding protein-regulated gene expression and cholesterol synthesis in HepG2 cells.

Reviews

Review for AMP-Deoxynojirimycin

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AMP-Deoxynojirimycin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.